scispace - formally typeset
F

Filip K. Knop

Researcher at University of Copenhagen

Publications -  523
Citations -  17834

Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.

Papers
More filters
Journal ArticleDOI

Current evidence for a role of GLP‐1 in Roux‐en‐Y gastric bypass‐induced remission of type 2 diabetes

TL;DR: This article critically evaluates the current evidence for a role of GLP‐1 in RYGB‐induced remission of T2DM and concludes that the former is likely to be a key mediator in the latter.
Journal ArticleDOI

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

TL;DR: It is demonstrated that inhibiting the K(ATP) channels of the diabetic beta-cell acutely using SU significantly increases both the peripheral insulin response to GIP and GIP-induced insulin secretion, indicating an ameliorated insulinotropic effect of GIP.
Journal ArticleDOI

Incretin-Based Therapy of Type 2 Diabetes Mellitus

TL;DR: Two new drug classes based on the actions of the incretin hormones have recently been approved for therapy of T2DM; injectable long-acting stable analogues of GLP-1, incret in mimetics, and orally available inhibitors of dipeptidyl peptidase 4 (DPP4; the enzyme responsible for the rapid degradation of GLp-1 and GIP), the so-called incretIn enhancers.
Journal ArticleDOI

Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young—Type 2 and Type 3

TL;DR: HNF1A-diabetes, similar to type 2 diabetes, is characterized by an impaired incretin effect and inappropriate glucagon responses, whereas incretIn effect and glucagon response to oral glucose remain unaffected in GCK-di diabetes, reflecting important pathogenetic differences between the two MODY forms.